LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4

Eli Lilly and Company’s (LLY) shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. The company also issued its total revenue guidance for 2025 at the JP Morgan Healthcare Conference.Lilly’s total revenues for the fourth quarter fell short of expectations due to lower-than-expected sales of its popular GLP-1 drugs, Mounjaro for type II diabetes and Zepbound for obesity. In addition, lower-than-exp ...